Novan Inc

Novan — Corporate Update (January 2020)

15 slides from Novan's corporate update, Jan 3, 2020

  1. Slide 1: SB206 Molluscum Top-Line Efficacy Plus Sensitivity Analyses

    Exhibit 99.2 SB206 Molluscum Top-Line Efficacy Plus Sensitivity Analyses 3rd January 2020 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our plans to develop and commercialize our product candidates, including our interpretation of preclinical and clinical studies and the success and tim

  3. Slide 3: Webcast Agenda

    Webcast Agenda • B-SIMPLE1 and B-SIMPLE2: study design including demographics • Top-line efficacy: results and sensitivity analyses • SB206 and molluscum indication: possible path(s) forward • Novan, Inc: brief commentary – funding, operations and runway 3

  4. Slide 4: SB206 Phase 3 Study Design (B-SIMPLE1, B-SIMPLE2)

    SB206 Phase 3 Study Design (B-SIMPLE1, B-SIMPLE2) • Multi-center, randomized, double-blind, vehicle-controlled, parallel trials to evaluate the efficacy and Description safety of SB206 12% QD for the treatment of molluscum contagiosum (“molluscum” or “MC”) • ~340 subjects per pivotal trial • 2:1 (ac

  5. Slide 5: Study Demographics

    Study Demographics1 B-SIMPLE1 B-SIMPLE2 ITT Population2 352 355 Completed Week 12 Treatment 303 304 Dropout Rate 13.1% 15.5% Number of Sites 33 33 % Dermatologists 66.7% 69.7% Age (years) Mean 7.1 6.4 % Ages 2 to 17 95.2% 97.5% Gender Female 47.7% 48.5% Male 52.3% 51.5% Baseline Lesion Count Mean 18

  6. Slide 6: B-SIMPLE1 & B-SIMPLE2: ITT Population

    B-SIMPLE1 & B-SIMPLE2: ITT Population1 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle p-value p-value (n=236) (n=116) (n=237) (n=118) Primary Endpoint: Complete Clearance of 25.8% 21.6% p=0.375 30.0% 20.3% p=0.062 All Lesions at Week 12 Secondary Endpoint: Complete Clearance of 15.3% 10.3% p=0.202

  7. Slide 7: B-SIMPLE1 & B-SIMPLE2: PP Population

    B-SIMPLE1 & B-SIMPLE2: PP Population1 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle p-value p-value (n=192) (n=109) (n=194) (n=103) Primary Endpoint: Complete Clearance of 31.3% 21.1% p=0.074 36.1% 23.3% p=0.028 All Lesions at Week 12 Statistical significance achieved in the PP population for the

  8. Slide 8: B-SIMPLE1 & B-SIMPLE2: ITT Population, LOCF

    B-SIMPLE1 & B-SIMPLE2: ITT Population1, LOCF2 B-SIMPLE1 B-SIMPLE2 SB206 Vehicle SB206 Vehicle p-value p-value (n=236) (n=116) (n=237) (n=118) Primary Endpoint: Complete Clearance of All 26.7% 21.6% p=0.292 30.8% 20.3% p=0.044 Lesions at Week 12 Exploratory Endpoint3: Clearance of 95% Lesions 28.0% 2

  9. Slide 9: B-SIMPLE1 & B-SIMPLE2: Consistent and Supportive

    B-SIMPLE1 & B-SIMPLE2: Consistent and Supportive • Primary analysis and pre-specified sensitivity analyses demonstrated evidence of consistency across both studies • Evidence of consistency between the two studies includes: − Statistical test of heterogeneity (tests for variation in study outcomes b

  10. Slide 10: Cross Trial Comparison: Complete Clearance at Week 12

    Cross Trial Comparison: Complete Clearance at Week 121 40.0% 37.5% * 35.0% 30.0% 30.0% 27.7% 25.8% 25.0% 21.6% 20.3% 20.0% 18.2% 15.0% 10.0% 12% QD 12% 12% QD 12% 12% QD 12% 5.0% BID 12% treatable molluscum lesions at Week 12 Week at lesions molluscum treatable % of patients with complete clearance

  11. Slide 11: SB206: Summary of B-SIMPLE Results

    SB206: Summary of B-SIMPLE Results • SB206 failed to achieve statistically significant results for the primary endpoint. • B-SIMPLE2 was statistically significant for multiple pre-specified sensitivity analyses. • Similar analyses with B-SIMPLE1 demonstrated the trial is reasonably consistent and su

  12. Slide 12: Clinical and Regulatory Possible Path Forward

    Clinical and Regulatory Possible Path Forward • Subject to discussions with the U.S. Food and Drug Administration (FDA), the Company intends to utilize B-SIMPLE2 as one of the confirmatory trials for New Drug Application (NDA) submission. • Subject to securing additional near-term funding and FDA fe

  13. Slide 13: Funding and Operations Commentary

    Funding and Operations Commentary • Management, along with the Board of Directors, continues to explore both financial and strategic options in order to continue to progress SB206 for the molluscum indication as well as preserve the nitric oxide science and technology platform. • The Company will pr

  14. Slide 14: Publicly Reported Cash Runway

    Publicly Reported Cash Runway • As of September 30, 2019, the Company had $22.5 million in total cash, cash equivalents and restricted cash, which is targeted to fund operations into the first quarter of 2020. • This projected cash runway excludes the effect of potential sales of common stock under

  15. Slide 15: SB206 Molluscum Top-Line Efficacy Plus Sensitivity Analyses

    SB206 Molluscum Top-Line Efficacy Plus Sensitivity Analyses 3rd January 2020 15

Novan — Corporate Update (January 2020) on 6ix